Immunome (IMNM) Capital Expenditures (2019 - 2026)
Immunome's (IMNM) quarterly Capital Expenditures came in at $3.0 million in Q1 2026, down 18.09% YoY from $3.7 million in Q1 2025, and down 24.93% on a QoQ basis from $4.0 million in Q4 2025.
Immunome (IMNM) Capital Expenditures (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Capital Expenditures data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Capital Expenditures fell 18.09% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (down 11.93% YoY) and the FY2025 annual result came in at $9.7 million, up 35.02% from the prior year.
- Capital Expenditures slipped to $3.0 million in Q1 2026, from $4.0 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $4.4 million in Q3 2025 to a low of -$2.4 million in Q2 2025.
- A 5-year average of $1.3 million and a median of $408500.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures soared 3616.67% — and 2025, when it plunged 160.76%.
- Tracing IMNM's Capital Expenditures over 5 years: stood at $72000.0 in 2022, then declined by 20.83% to $57000.0 in 2023, then soared by 1875.44% to $1.1 million in 2024, then jumped by 255.15% to $4.0 million in 2025, then decreased by 24.93% to $3.0 million in 2026.
- The last three Capital Expenditures figures came in at $3.0 million (Q1 2026), $4.0 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.18 Mn |
| Jun 30, 2026 | 2.18 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 4.00 Mn |
| Dec 31, 2025 | 4.00 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | -2.38 Mn |
| Jun 30, 2025 | -2.38 Mn |
| Mar 31, 2025 | 3.67 Mn |
| Mar 31, 2025 | 3.67 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 3.91 Mn |
| Mar 31, 2024 | 594,000.00 |
| Mar 31, 2024 | 594,000.00 |